Schedule
Day 1
Tuesday the 9th of September 2025
- 13:00 - 15:00
-
Registration
Tea, coffee and poster set up.
- 15:00 - 15:15
-
Welcome and opening remarks
To be given by Andrew Chalmers & Carly Dix.
Session 1
Chair: Andrew Chalmers, CiteAb, UK
- 15:15 - 15:35
-
Ulf Landegren, Uppsala University, SE
Minimizing antibody cross-reactivity and revealing dynamic protein activity states via dual recognition in solution and in situ.
- 15:35 - 15:55
-
Amy Turner, Proteintech, UK
Epitope-Mapped Recombinant Antibodies: A New Standard in Antibody Validation.
- 15:55 - 16:10
-
Stefan Schuechner, Medical University of Vienna, AT
Protein Phosphatase 2A carboxy terminus: how insufficient validation of post-translational modification specific antibodies misled the field for over 20 years.
- 16:10 - 16:30
-
Carly Dix, AstraZeneca, UK
Overcoming Antibody Selection, Validation, and Generation Challenges to Accelerate the Discovery of New Medicines.
- 16:30 - 18:00
-
Drinks reception
Day 2
Wednesday the 10th of September 2025
- 09:00 - 09:30
-
Open
Tea, coffee and pastries
Session 2
Chair: Alejandra Solache, Abcam, UK
- 09:30 - 09:50
-
Andrew Bradbury, Specifica, an IQVIA business, US
The AIntibody challenge: an update on the use of AI/ML in antibody discovery.
- 09:50 - 10:10
-
Will Howat, Abcam, UK
Antibody Quality is not just about specificity.
- 10:10 - 10:30
-
Libby Wiseman, AstraZeneca, UK
The impact of pre-analytical factors on immunohistochemistry assays that detect labile Phospho-epitopes.
- 10:30 - 11:00
-
Break
Tea, coffee, posters and sponsors' exhibition
Session 3
Chair: Asel Sartbaeva, University of Bath, UK
- 11:00 - 11:20
-
Johan Duchêne, Ludwig Maximilian University of Munich, DE
The DARC Side of Antibodies.
- 11:20 - 11:40
-
Nidhi Nath, Bio-Techne, US
Antibody Development and Validation in the Era of Spatial Proteomics.
- 11:40 - 12:00
-
Myriam Duckely, Novartis, CH
Tool antibodies in early drug discovery.
- 12:00 - 13:15
-
Lunch
Lunch, posters and sponsors' exhibition
Session 4 (short talks)
- 13:15 - 13:30
-
Elisia Clark, The Michael J. Fox Foundation, US
Research Resources for Tool Validation through the Michael J. Fox Foundation.
- 13:30 - 13:45
-
Ruth McAdam, GlaxoSmithKline, UK
A view from Pharma: Custom antibody sourcing at GSK.
- 13:45 - 14:00
-
Jim Trimmer, University of California, Davis, US
Open-Source Antibodies as a Path to Enhanced Research Reproducibility and Transparency.
- 14:00 - 14:15
-
Jonathan Schmid-Burgk, University of Bonn, DE
Pooled validation screening and affinity maturation of AI-designed protein binders.
- 14:15 - 14:30
-
Björn Forsström, Olink Proteomics, SE
Expanding validation of Proximity Extension Assays.
- 14:30 - 16:00
-
Poster session
Tea, coffee, posters and sponsors' exhibition
- 16:00 - 16:20
-
Deborah Moshinsky, Institute for Protein Innovation (IPI), US
Systematic Antibody Validation for Community Distribution Using High-Throughput Biophysical and Functional Testing.
- 16:20 - 16:40
-
Roberto Polakiewicz, Cell Signaling Technology, US
Antibody validation in the age of spatial and single cell biology.
- 16:40 - 17:00
-
Andrew Buchanan, Stealth Mode Biotech, UK
- 19:30 - late
-
Conference dinner
Conference social event (Hilton, Bath)
Session 5
Chair: Katarzyna Kmiecik, Alchemab Therapeutics, UK
Day 3
Thursday the 11th of September 2025
- 09:00 - 09:30
-
Open
Tea, coffee and pastries
Session 6
Chair: Elena Ivanova, Regeneron, US
- 09:30 - 09:50
-
Michael Weiner, Precision BioTools, US
MILKSHAKE and Sundae: Sweet Solutions to the Bitter Problem of anti-PTM Specific Antibody Validation.
- 09:50 - 10:10
-
Leticia Montoya, Thermo Fisher Scientific, US
Accelerating spatial proteomics research with Thermo Fisher Scientific's specificity verified antibodies.
- 10:10 - 10:30
-
Carl Laflamme, Neuro-SGC, YCharOS initiative, CA
Antibody Validation as a Scientific Discipline: Lessons and Challenges from YCharOS.
- 10:30 - 10:45
-
Zoé Butti, New York Genome Center, US
Mapping the Cellular Landscape of Protein Aggregation Across ALS, FTD, and Alzheimer's Disease.
- 10:45 - 11:15
-
Break
Tea, coffee, posters and sponsors' exhibition
Session 7
Chair: Carly Dix, AstraZeneca, UK
- 11:15 - 11:35
-
Elena Ivanova, Regeneron, US
What does a scientist need to select an IHC antibody?
- 11:35 - 11:55
-
Thierry Le Bihan, Rapid Novor, CA
One Clone to Rule Them All: Turning pAbs into rAbs.
- 11:55 - 12:15
-
Andrea Radtke, Leica Microsystems, US
It takes a community: Impact of HuBMAP and grassroots efforts to characterize antibodies for spatial biology applications.
Closing remarks
To be given by Andrew Chalmers & Carly Dix
